Incyte Will Present Multiple Dermatology Abstracts at AAD 2023

wellphoto/AdobeStock

Multiple abstracts from Incyte’s dermatology portfolio will be presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting next week, March 17-21, 2023, in New Orleans, Louisiana. Most notably, 3 late-breaking presentations for vitiligo treatments will highlight new long-term data from the phase 3 TruE-V trials of ruxolitinib cream, as well as data from a phase 2b study of povorcitinib.

The first 2 late-breaking presentations for vitiligo treatments will review phase 3 data of TRuE-V evaluating the durability and long-term response of ruxolitinib cream in patients 12 years and older with vitiligo. The phase 3 data builds on previously announced positive 24- and 52-week results from TRuE-V1 and TRuE-V2 studies. The third late-breaking presentation will review safety and efficacy data from a phase 2b study of povorcitinib, an investigational oral small-molecule Janus Kinase (JAK) 1 inhibitor for patients with vitiligo. 

Listed below are key oral and e-abstracts featured at AAD:

Late-Breaking Oral Presentations: Vitiligo

1. Relapse and Maintenance of Clinical Response in the Randomized Withdrawal Arm of the TRuE-V Long-Term Extension Phase 3 Study of Ruxolitinib Cream in Vitiligo (Session: S025 – Late-Breaking Research: Session 1. Saturday, March 18, 9:20 a.m. CT)
2. Facial and Total Vitiligo Area Scoring Index Response Shift During 104 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Results from the Open-Label Arm of the TRuE-V Long-Term Extension Phase 3 Study (Session: S025 – Late-Breaking Research: Session 1. Saturday, March 18, 9:30 a.m. CT)
3. Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 – Late-Breaking Research: Session 2. Saturday, March 18, 2:30 p.m. CT)

Posters with Oral Presentation

Atopic Dermatitis

1. Ruxolitinib Cream Monotherapy Use Demonstrates Maintenance of Disease and Symptom Control with Use as Needed in Adults and Adolescents with Atopic Dermatitis: Pooled Analysis from the Long-Term Safety Periods of Two Phase 3 Studies (Abstract #44103. Session: Atopic Dermatitis. Friday, March 17, 2023, 3:20 p.m. – 3:25 p.m. CT)

Hidradenitis Suppurativa

1. Changes in Draining Tunnel (dT) Counts in the Randomized, Placebo-Controlled, Phase 2 Study of Povorcitinib (INCB054707) in Patients with Hidradenitis Suppurativa (HS) (Abstract #44062. Session: Immunodermatology & Blistering Disorders. Saturday, March 18, 2023, 10:40 a.m. – 10:45 a.m. CT)

Vitiligo

1. Vitiligo Noticeability Scale Score Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43959. Session: Pigmentary Disorders & Vitiligo. Saturday, March 18, 2023, 5:50 p.m. – 5:55 p.m. CT)
2. Facial Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43912. Session: Pigmentary Disorders & Vitiligo. Saturday, March 18, 2023, 5:35 p.m. – 5:40 p.m. CT)

e-Poster Exhibits

Virtual abstracts will be available in the online viewing portal starting March 17th at 7:00 a.m. CDT and on-site at the viewing stations. They will also be published online in the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2023.

Graft-Versus-Host Disease (GVHD)

1. Oral Ruxolitinib Treatment for Patients with Dermatologic Manifestations of Acute or Chronic Graft-Versus-Host Disease: A Post Hoc Analysis of the Phase 3 REACH2 and REACH3 Studies (Session: Immunodermatology & Blistering Disorders.)

Vitiligo

1. Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies (Abstract #43938. Session: Pigmentary Disorders & Vitiligo.)
2. Treatment-Emergent Adverse Events of Interest for Janus Kinase Inhibitors: Pooled Analysis of the 52-Week TRuE-V Phase 3 Studies of Ruxolitinib Cream Treatment for Vitiligo (Abstract #43978. Session: Pigmentary Disorders & Vitiligo.)

For questions about Incyte’s portfolio and data, Incyte will host an in-person analyst and investor event on Saturday, March 18, 2023, from 5:30-7:30 p.m. CT. The event will also be virtually broadcast, and more details can be found on Incyte’s website.

Reference

1. Multiple abstracts from Incyte’s growing dermatology portfolio featured at American Academy of Dermatology (AAD) Annual Meeting. Incyte. Published March 6, 2023. Accessed March 7, 2023. https://investor.incyte.com/news-releases/news-release-details/multiple-abstracts-incytes-growing-dermatology-portfolio